281 VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells. (September 2015) - Kolev, V.; Wang, Y.; Sprott, K.; Padval, M.; Pachter, J.; Weaver, D.